$MTEK
Maris Tech Ltd. Stock $mtek

$mtek Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024024527 Filed on March 21, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$3.557M	$4.031M	$1.537M
YoY Change	131.45%	60.93%	-99.79%
Cost Of Revenue	$1.459M	$2.104M	$1.071M
YoY Change	36.25%	22.16%	-99.77%
Gross Profit	$2.098M	$1.927M	$466.0K
YoY Change	350.21%	146.22%	-99.84%
Gross Profit Margin	58.98%	47.81%	30.32%
Selling, General & Admin	$1.988M	$3.802M	$1.488M
YoY Change	33.6%	33.85%	-99.69%
% of Gross Profit	94.77%	197.27%	319.34%
Research & Development	$613.9K	$1.055M	$371.5K
YoY Change	65.26%	3.23%	-99.88%
% of Gross Profit	29.26%	54.73%	79.71%
Depreciation & Amortization	$30.65K	$60.65K	$12.96K
YoY Change	136.5%	252.39%	-99.51%
% of Gross Profit	1.46%	3.15%	2.78%
Operating Expenses	$2.602M	$4.857M	$1.860M
YoY Change	39.93%	8.74%	-99.76%
Operating Profit	-$504.1K	-$2.930M	-$1.394M
YoY Change	-63.83%	-179.53%	-99.72%
Interest Expense	$58.53K	$220.0K	-$21.04K
YoY Change	-378.18%	617.02%	-99.99%
% of Operating Profit
Other Income/Expense, Net		$220.0K
YoY Change		4794.46%
Pretax Income	-$445.6K	-$2.710M	-$1.415M
YoY Change	-68.5%	-26.54%	-99.81%
Income Tax
% Of Pretax Income
Net Earnings	-$445.6K	-$2.710M	-$1.415M
YoY Change	-68.5%	-26.54%	-99.81%
Net Earnings / Revenue	-12.53%	-67.22%	-92.04%
Basic Earnings Per Share		-$0.34
Diluted Earnings Per Share	-$0.06	-$0.34	-$0.18
COMMON SHARES
Basic Shares Outstanding	7.879M shares	7.908M shares	7.999M shares
Diluted Shares Outstanding		7.908M shares

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.199M	$5.199M	$222.0K
YoY Change	2242.42%	2242.42%	-71.72%
Cash & Equivalents	$2.050M	$2.050M	$222.0K
Short-Term Investments	$3.149M	$3.149M
Other Short-Term Assets			$9.084M
YoY Change
Inventory	$1.960M	$1.960M	$981.7K
Prepaid Expenses
Receivables	$2.990M	$2.990M	$1.606M
Other Receivables	$172.8K	$172.8K	$359.6K
Total Short-Term Assets	$10.32M	$10.32M	$12.25M
YoY Change	-15.77%	-15.77%	-98.73%
LONG-TERM ASSETS
Property, Plant & Equipment	$313.6K	$817.2K	$283.8K
YoY Change	10.52%	-11.16%	-98.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$194.8K	$194.8K	$190.3K
YoY Change	2.34%	2.34%	-99.98%
Total Long-Term Assets	$1.012M	$1.012M	$1.110M
YoY Change	-8.84%	-8.84%	-99.9%
TOTAL ASSETS
Total Short-Term Assets	$10.32M	$10.32M	$12.25M
Total Long-Term Assets	$1.012M	$1.012M	$1.110M
Total Assets	$11.33M	$11.33M	$13.36M
YoY Change	-15.19%	-15.19%	-99.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.215M	$1.215M	$1.083M
YoY Change	12.12%	12.12%	-99.77%
Accrued Expenses	$337.0K	$337.0K	$316.9K
YoY Change	6.35%	6.35%	-99.94%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$498.8K	$498.8K	$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$3.058M	$3.058M	$1.811M
YoY Change	68.85%	68.85%	-99.91%
LONG-TERM LIABILITIES
Long-Term Debt	$589.5K	$589.5K
YoY Change		-45.83%
Other Long-Term Liabilities	$792.3K	$792.3K	$867.9K
YoY Change	-8.72%	-8.72%	-99.86%
Total Long-Term Liabilities	$1.382M	$1.382M	$1.956M
YoY Change	-29.37%	-29.37%	-99.92%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.058M	$3.058M	$1.811M
Total Long-Term Liabilities	$1.382M	$1.382M	$1.956M
Total Liabilities	$4.439M	$4.439M	$3.767M
YoY Change	17.85%	17.85%	-99.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$10.90M		-$8.193M
YoY Change	33.07%		81.89%
Common Stock	$17.92M		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.894M	$6.894M	$9.597M
YoY Change
Total Liabilities & Shareholders Equity	$11.33M	$11.33M	$13.36M
YoY Change	-15.19%	-15.19%	-99.34%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$445.6K	-$2.710M	-$1.415M
YoY Change	-68.5%	-26.54%	-99.81%
Depreciation, Depletion And Amortization	$30.65K	$60.65K	$12.96K
YoY Change	136.5%	252.39%	-99.51%
Cash From Operating Activities	-$1.621M	-$3.871M	-$1.907M
YoY Change	-15.0%	-20.3%	-98.37%
INVESTING ACTIVITIES
Capital Expenditures	$20.51K	$90.51K	$219.8K
YoY Change	-90.67%	-68.19%	-154.94%
Acquisitions
YoY Change
Other Investing Activities	$1.909M	$5.909M	$2.002M
YoY Change	-4.66%	-165.51%	-112.79%
Cash From Investing Activities	$1.888M	$5.818M	$1.782M
YoY Change	5.95%	-162.53%	-111.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	460.0	-$119.5K	0.000
YoY Change		-100.83%	-100.0%
NET CHANGE
Cash From Operating Activities	-1.621M	-$3.871M	-1.907M
Cash From Investing Activities	1.888M	$5.818M	1.782M
Cash From Financing Activities	460.0	-$119.5K	0.000
Net Change In Cash	267.6K	$1.828M	-124.9K
YoY Change	-314.26%	785.48%	-99.88%
FREE CASH FLOW
Cash From Operating Activities	-$1.621M	-$3.871M	-$1.907M
Capital Expenditures	$20.51K	$90.51K	$219.8K
Free Cash Flow	-$1.642M	-$3.962M	-$2.127M
YoY Change	-22.82%	-22.95%	-98.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39957
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Yitzhak Modai Street
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Rehovot
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7608804
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7878501	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	1281
CY2023	dei	Auditor Name AuditorName	KOST FORER GABBAY & KASIERER
CY2023	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2050494	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221961	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	3148746	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	9084082	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2990305	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1606495	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	172809	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	359591	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1959651	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	981729	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	10322005	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	12253858	usd
CY2023Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	32692	usd
CY2022Q4	us-gaap	Restricted Investments Noncurrent RestrictedInvestmentsNoncurrent	33569	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313649	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	283790	usd
CY2023Q4	mtek	Severance Pay Deposits SeverancePayDeposits	162053	usd
CY2022Q4	mtek	Severance Pay Deposits SeverancePayDeposits	156723	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	503507	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	635976	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1011901	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1110058	usd
CY2023Q4	us-gaap	Assets Assets	11333906	usd
CY2022Q4	us-gaap	Assets Assets	13363916	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1214621	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1083345	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1344284	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	727560	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3057686	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1810905	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	323071	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	442166	usd
CY2023Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	469191	usd
CY2022Q4	us-gaap	Supplemental Unemployment Benefits Severance Benefits SupplementalUnemploymentBenefitsSeveranceBenefits	425742	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1381730	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1956158	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4439416	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3767063	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7999216	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7999216	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7878501	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9596853	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11333906	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13363916	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4031103	usd
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7999216	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	120715	shares
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	119536	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17916149	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	17789380	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10902123	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8192527	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6894490	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2504896	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2075755	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2103707	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1722104	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1106447	usd
CY2023	us-gaap	Gross Profit GrossProfit	1927396	usd
CY2022	us-gaap	Gross Profit GrossProfit	782792	usd
CY2021	us-gaap	Gross Profit GrossProfit	969308	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1054895	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1021869	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	706021	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	874793	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	604114	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	241114	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2927310	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2840660	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	595074	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4856998	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	4466643	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1542209	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-2929602	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-3683851	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-572901	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	220006	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4495	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-251323	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2709596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7908266	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7528038	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3464470	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2601149	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1045793	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-2379580	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15176584	usd
CY2022	us-gaap	Reclassifications Of Temporary To Permanent Equity ReclassificationsOfTemporaryToPermanentEquity	412299	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	75896	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9596853	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	126769	usd
CY2023	mtek	Repurchase Of Treasury Shares RepurchaseOfTreasuryShares	119536	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2709596	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6894490	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2709596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2023	us-gaap	Depreciation Depreciation	60649	usd
CY2022	us-gaap	Depreciation Depreciation	17211	usd
CY2021	us-gaap	Depreciation Depreciation	5056	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	60454	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	77551	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	126769	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	75896	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-18237	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	133816	usd
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	39731	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	43449	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	153233	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	55052	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1383810	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1035013	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	443944	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-186782	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	356718	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	95	usd
CY2023	mtek	Increase In Inventories IncreaseInInventories	977922	usd
CY2022	mtek	Increase In Inventories IncreaseInInventories	590245	usd
CY2021	mtek	Increase In Inventories IncreaseInInventories	140417	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	131276	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	619692	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	213859	usd
CY2023	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	633009	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	20625	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	221891	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3871157	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4857027	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-875002	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	6000000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	12500000	usd
CY2023	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	12000000	usd
CY2022	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	3500000	usd
CY2022	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	20103	usd
CY2021	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	21457	usd
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	200000	usd
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	108857	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	90508	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	284490	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7967	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	5818349	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9304593	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29424	usd
CY2022	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-410324	usd
CY2021	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt	-56638	usd
CY2021	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	199547	usd
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	119536	usd
CY2022	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	17824992	usd
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	1500000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2101875	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	179913	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	183038	usd
CY2022	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	744769	usd
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	125247	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	200000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	621607	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-119536	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14368024	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	899180	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1827656	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	206404	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-5245	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255530	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49126	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54371	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2083186	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255530	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	49126	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	5934	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	16882	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	15372	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	157627	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8686	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	154	usd
CY2021	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost	249564	usd
CY2022	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity	412299	usd
CY2023	mtek	Working Capital Deficit WorkingCapitalDeficit	7264319	usd
CY2022	mtek	Working Capital Deficit WorkingCapitalDeficit	10442953	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10902123	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8192527	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3871157	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4857027	usd
CY2022Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4244048	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	4244048	shares
CY2022Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	17824992	usd
CY2022Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	15101508	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1336875	usd
CY2022Q1	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	1386608	usd
CY2022Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	1355093	usd
CY2022Q1	us-gaap	Repayments Of Debt RepaymentsOfDebt	1355093	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	Use of estimates:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in">The preparation of the financial statements in conformity with U.S GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during reported periods. The Company’s management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they are made. Actual results could differ from those estimates.</p>
CY2023Q4	us-gaap	Other Receivables OtherReceivables	324960	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	78485	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	11856	usd
CY2022	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3220	usd
CY2021	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5850	usd
CY2023	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	30596	usd
CY2021Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	871171	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25049	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	20758	usd
CY2020Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	9879	usd
CY2023	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	15334	usd
CY2022	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	7511	usd
CY2021	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	16729	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	40311	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25049	usd
CY2021Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	20758	usd
CY2023	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet	259473	usd
CY2022	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet	98138	usd
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5685694	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5206700	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	379772	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	120715	shares
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	81212	usd
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	61169	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	31356	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	Concentrations of credit or business risk:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in"><span>Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, bank deposits, trade receivables and trade payables.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in"><span>Cash equivalents and bank deposits are invested mainly in NIS and U.S. dollars with major banks in Israel. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in"><span>Most of the Company’s trade receivables are derived from sales to large and financially secure</span> organizations. In determining the adequacy of the allowance, management bases its opinion, inter alia, on the estimated risks, current market conditions and in reliance on available information with respect to the debtor’s financial position. See Note 10b for a discussion of the Company’s major customers<span>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: left; text-indent: 0in">The Company acquires certain component parts for its products from market leading suppliers that are single source manufacturers. In order to mitigate the risk and as a redundant solution, the Company designs similar products based on component parts from different suppliers.</p>
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.35
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2050494	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	221961	usd
CY2023Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	32692	usd
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	33569	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2083186	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	255530	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	530444	usd
CY2023	srt	Interest Bearing Deposits In Banks Average Yield InterestBearingDepositsInBanksAverageYield	0.011	pure
CY2022	srt	Interest Bearing Deposits In Banks Average Yield InterestBearingDepositsInBanksAverageYield	0.011	pure
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1101957	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	551774	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	857694	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	429955	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1959651	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	981729	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	407591	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	317083	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	93942	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33293	usd
CY2023Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	313649	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	283790	usd
CY2023	us-gaap	Depreciation Depreciation	60649	usd
CY2022	us-gaap	Depreciation Depreciation	17211	usd
CY2021	us-gaap	Depreciation Depreciation	5056	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	130690	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	128283	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	128283	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	106865	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	494121	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	43260	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	450861	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M21D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0508	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0508	pure
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	96910	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	126966	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	56040	usd
CY2023	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	153833	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	117314	usd
CY2021	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	78125	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	760350	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	357188	usd
CY2023Q4	us-gaap	Extended Product Warranty Accrual Current ExtendedProductWarrantyAccrualCurrent	40311	usd
CY2022Q4	us-gaap	Extended Product Warranty Accrual Current ExtendedProductWarrantyAccrualCurrent	25049	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	209212	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	172818	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	127790	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	144076	usd
CY2023Q4	mtek	Government Authorities GovernmentAuthorities	206621	usd
CY2022Q4	mtek	Government Authorities GovernmentAuthorities	28429	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1344284	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	727560	usd
CY2021Q4	us-gaap	Guarantee Obligations Current Carrying Value GuaranteeObligationsCurrentCarryingValue	1355306	usd
CY2023Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	450000	usd
CY2022Q3	us-gaap	Grants Receivable GrantsReceivable	1314024	ils
CY2022Q3	us-gaap	Grants Receivable GrantsReceivable	362290	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	721426	ils
CY2023Q2	us-gaap	Grants Receivable GrantsReceivable	1209797	ils
CY2023Q2	us-gaap	Grants Receivable GrantsReceivable	333553	usd
CY2023Q2	mtek	Grant Percentage Of Total Budget GrantPercentageOfTotalBudget	0.50	pure
CY2023Q4	mtek	Grant Project Amount GrantProjectAmount	935544	ils
CY2023Q4	mtek	Grant Project Amount GrantProjectAmount	257939	usd
CY2023Q4	mtek	Percentage Of Grants PercentageOfGrants	0.66	pure
CY2023Q4	us-gaap	Proceeds From Grantors ProceedsFromGrantors	170240	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	59584	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4031103	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2504896	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2075755	usd
CY2023Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	182735	usd
CY2022Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	237982	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	97265	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	90122	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	4031103	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2504896	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2075755	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-2709596	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3688346	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-824224	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7908266	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7528038	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3464470	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7999216	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7878501	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	489812	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	489812	shares
CY2023	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	489812	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	185023	shares
CY2022Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	1000000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	120715	shares
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	119536	usd
CY2023Q1	mtek	Percentage Of Ordinary Shares Outstanding PercentageOfOrdinarySharesOutstanding	0.015	pure
CY2023Q1	mtek	Percentage Of Ordinary Shares Issued PercentageOfOrdinarySharesIssued	0.015	pure
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.987
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1500000	usd
CY2021Q1	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	489812	shares
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	7.9888
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	274294	usd
CY2023	mtek	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.05	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	24491	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	3.06
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company’s general meeting of shareholders approved a reverse share split of the Ordinary Shares and the Preferred Shares, at a ratio of 4:1 (four-to-one), so that holders of Ordinary Shares and Preferred Shares will receive one Ordinary share and one Preferred share, respectively, for every four Ordinary Shares and Preferred Shares held as of such date rounded to the nearest number (with 0.5 share rounded up), and to adopt an amendment to the Company’s Articles of Association to effectuate such reverse stock split.
CY2021Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	489812	usd
CY2022Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	412299	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	60454	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	285422	shares
CY2023Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	58818	usd
CY2023	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	16642	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	27659	usd
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	12070	usd
CY2023	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	70398	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	126769	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	234300	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P3Y10M20D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	17874	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1
CY2023	mtek	Share Based Compensation Arrangementby Share Based Payment Award Options Weighted Average Remaining Contractual Granted Term Weighted Average Remaining Contractual Term Forfeited ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualGrantedTermWeightedAverageRemainingContractualTermForfeited	P2Y10M20D
CY2023	mtek	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited	0.05	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	216426	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1
CY2023	mtek	Share Based Compensation Arrangementby Share Based Payment Award Options Weightedaverageremainingcontractualterm ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsWeightedaverageremainingcontractualterm	P2Y10M20D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0.05	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5468	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1
CY2023	mtek	Share Based Compensation Arrangementby Share Based Payment Award Optionsexercisable Weightedaverageremainingcontractualterm ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsexercisableWeightedaverageremainingcontractualterm	P2Y10M20D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0.05	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	1.09
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	210958	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	160320	usd
CY2023	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M20D
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.12	pure
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.25	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1845821	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1218869	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	218728	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	189856	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	9584	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves	5761	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	69048	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	49850	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	70656	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Severance Payments DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsSeverancePayments	62060	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses	74741	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	184781	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Other DeferredTaxAssetsTaxDeferredExpenseOther	381090	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	103698	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	134836	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2577057	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	2042322	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2473359	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1907486	usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	103698	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	134836	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	103698	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	134836	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	103698	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	134836	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1907486	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	914171	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	565873	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	993315	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2473359	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	1907486	usd
CY2023	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	the Company entered into a loan facility agreement (the “Loan Facility Agreement”), effective as of January 1, 2021, with Mr. Bar and Mr. Gottlieb.As part of the Agreement, the amount to be paid to Mr. Bar is approximately NIS 2,459,959 (approximately $770,879) and to Mr. Gottlieb, is approximately NIS 1,020,347 (approximately $317,371). The Loan Facility Agreement, bears no interest and shall be due and payable in 24 equal monthly payments, commencing on the second anniversary following completion of an initial public offering. Pursuant to the Loan Facility Agreement, if an initial public offering is not completed by December 31, 2021, then the outstanding amount shall be repaid pursuant to the available free cash of the Company, taking into account expected expenditures in the three months following partial or full payment, and in any event not prior to December 31, 2022. The Company also agreed to reimburse Mr. Bar and Mr. Gottlieb for any costs and expenses incurred in connection with the enforcement of the Loan Facility Agreement, if required. The agreement was accounted for as a modification with no change to the book value of the loan. As of December 31, 2023 the outstanding amount under the Loan Facility Agreement is $1,088,250. On March 2, 2023, the Company entered into an amendment (the “Amendment”) to the Loan Facility Agreement, pursuant to which the Company (i) amended the repayment terms set in the Loan Facility Agreement to provide that the amounts outstanding under the Loan Facility Agreement shall be due and payable in 24 equal monthly payments, commencing on February 4, 2024, subject to availability of available free cash (as defined in the Amendment) of the Company and (ii) clarified the total amount due to Mr. Gottlieb under the Loan Agreement is NIS 1,020,347 (approximately $317,371). Pursuant to the Amendment, the total outstanding amount under the Loan Facility Agreement after giving effect to the Amendment was NIS 3,480,306 (approximately $1,088,250). The agreement was accounted for as a modification with no change to the book value of the loan.
CY2023Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	108857	usd
CY2023Q3	mtek	Financial Expense FinancialExpense	91143	usd
CY2021Q1	mtek	Compensation Expense CompensationExpense	54	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	97	usd
CY2023	mtek	Interest Income Expense On Bank Deposits InterestIncomeExpenseOnBankDeposits	251724	usd
CY2022	mtek	Interest Income Expense On Bank Deposits InterestIncomeExpenseOnBankDeposits	-92768	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	12254	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	23156	usd
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	80686	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	60454	usd
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	77551	usd
CY2023	mtek	Remeasurement Of The Investment RemeasurementOfTheInvestment	91305	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-71841	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	13653	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	93086	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	220006	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4495	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-251323	usd
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity Registrant Name EntityRegistrantName	Maris Tech Ltd.
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue		usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares		shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2021	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
CY2023	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2023	us-gaap	Proceeds From Repayments Of Short Term Debt ProceedsFromRepaymentsOfShortTermDebt		usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity		usd
CY2023	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity		usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2023	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt		usd
CY2023	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt		usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
CY2023	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost		usd
CY2022	mtek	Noncash Deferred Issuance Cost NoncashDeferredIssuanceCost		usd
CY2023	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity		usd
CY2021	us-gaap	Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q4	us-gaap	Other Receivables OtherReceivables		usd
CY2021	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2021	us-gaap	Research And Development Arrangement With Federal Government Costs Incurred Net ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet		usd
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3464470	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7528038	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7908266	shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023	mtek	Share Based Compensation Arrangementby Share Based Payment Award Options Grants Weighted Average Remaining Contractual Granted Term Granted ShareBasedCompensationArrangementbyShareBasedPaymentAwardOptionsGrantsWeightedAverageRemainingContractualGrantedTermGranted
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested		usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Provision For Loan Losses DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021Q1	mtek	Compensation Expense CompensationExpense	195	ils
CY2022Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	350	ils
CY2021	mtek	Interest Income Expense On Bank Deposits InterestIncomeExpenseOnBankDeposits		usd
CY2023	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001872964

Files In Submission

Name	View Source	Status
0001213900-24-024527-index-headers.html	Edgar Link	pending
0001213900-24-024527-index.html	Edgar Link	pending
0001213900-24-024527.txt	Edgar Link	pending
0001213900-24-024527-xbrl.zip	Edgar Link	pending
ea0202119-20f_maris.htm	Edgar Link	pending
ea020211901ex12-1_maristech.htm	Edgar Link	pending
ea020211901ex12-2_maristech.htm	Edgar Link	pending
ea020211901ex13-1_maristech.htm	Edgar Link	pending
ea020211901ex13-2_maristech.htm	Edgar Link	pending
ea020211901ex15-1_maristech.htm	Edgar Link	pending
ea020211901ex15-2_maristech.htm	Edgar Link	pending
ea020211901ex2-4_maristech.htm	Edgar Link	pending
ea020211901ex4-17_maristech.htm	Edgar Link	pending
ea020211901ex97-1_maristech.htm	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_026.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
ea0202119-20f_maris_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
image_028.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mtek-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
mtek-20231231_def.xml	Edgar Link	unprocessable
mtek-20231231_lab.xml	Edgar Link	unprocessable
mtek-20231231_pre.xml	Edgar Link	unprocessable
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
mtek-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MTEK
Maris Tech Ltd. Stock $mtek

2023 Q4 Form 20-F Financial Statement

#000121390024024527 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEK Maris Tech Ltd. Stock $mtek

2023 Q4 Form 20-F Financial Statement

#000121390024024527 Filed on March 21, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MTEK
Maris Tech Ltd. Stock $mtek